Story perspectives

Supreme Court Extends Stay, Keeps Telehealth Mifepristone Access

5/15/2026

Summary

Supreme Court Blocks

The U.S. Supreme Court extended its stay, blocking enforcement of a lower-court order that would limit mail and telehealth access to the abortion pill mifepristone.
The stay preserves FDA rules allowing telehealth prescribing and mail delivery of mifepristone and blocks the Fifth Circuit’s May 1 decision reinstating Louisiana’s in-person requirement.
Justice Clarence Thomas dissented, with Justice Samuel Alito filing a separate dissent that criticized the majority’s action.

Summary

Louisiana Investigates

Louisiana spent over $17,000 investigating out-of-state providers who mailed mifepristone into the state.
The state seeks thousands of Medicaid dollars for medication abortions, which made up 65% of clinician-provided abortions in 2023.
Over 1.1 million abortions occurred last year, many delivered via telehealth and mail-order services.
Medical groups report adverse events in fewer than 0.32% of mifepristone patients, while anti-abortion groups have sued over the FDA’s 2000 approval on safety grounds.

Summary

Thomas Cites Comstock

Justice Clarence Thomas cited the 1873 Comstock Act in his dissent to Supreme Court’s mifepristone order.
U.S. President Donald Trump’s administration filed no brief in the case.
The administration’s mifepristone review is described as politically motivated to restrict the drug while activists invoke the long-unenforced Comstock Act to limit mail-order abortion pills.
FDA Commissioner Marty Makary resigned after months of criticism from Trump-aligned anti-abortion groups over the agency’s mifepristone review.

Summary

California Prepares

California's network of providers and pharmaceutical suppliers prepared a contingency plan to keep dispensing abortion medication if the Supreme Court blocks mail-order mifepristone.
The Senate Democratic caucus reintroduced a resolution, backed by all 45 Democratic senators, affirming mifepristone’s safety and effectiveness.
Alliance Defending Freedom, winner of the 2024 FDA v. Alliance for Hippocratic Medicine case, represents Louisiana in a lawsuit that could let a state override federal drug-regulation authority nationwide.

History

Historical Context

The 1973 Supreme Court ruling in Roe v. Wade, a 7-2 decision, protected first-trimester abortions nationwide. After Dobbs v. Jackson overturned that right in 2022, the Court in 2024 issued a stay preserving the FDA’s telehealth rules for the abortion pill mifepristone, while Justices Thomas and Alito cited the 1873 Comstock Act to contest mail-order distribution.

1 of 5

Supreme Court Blocks

The U.S. Supreme Court extended its stay, blocking enforcement of a lower-court order that would limit mail and telehealth access to the abortion pill mifepristone.
The stay preserves FDA rules allowing telehealth prescribing and mail delivery of mifepristone and blocks the Fifth Circuit’s May 1 decision reinstating Louisiana’s in-person requirement.
Justice Clarence Thomas dissented, with Justice Samuel Alito filing a separate dissent that criticized the majority’s action.

1 / 5